Personalized Medicine Funding Opportunities
The Personalized Medicine Signature Initiative plans to launch a number of dedicated funding opportunities over the next several years.March 2013
Operating Grant: Collaborative Health Research Projects (NSERC Partnered)
The Collaborative Health Research Projects (CHRP) program is a joint initiative between the Natural Sciences and Engineering Research Council (NSERC) and the Canadian Institutes of Health Research (CIHR). The CHRP program supports innovative interdisciplinary collaborative research projects requiring participation from the natural sciences or engineering community together with the health sciences community. The Institute of Cancer Research (ICR) has partnered with the CHRP program to advance the Personalized Medicine Signature Initiative research agenda. ICR will support the development and validation of diagnostics based on biomarkers, targets and genomic signatures, as well as of innovative devices for the application to patient practice.
July 2012
Operating Grant: Bioinformatics and Computational Biology
Genome Canada, in partnership with the Canadian Institutes of Health Research (CIHR), is seeking proposals for research projects to address any aspect of bioinformatics and computational biology (B/CB) as it relates to genomics. Through this Genome Canada and CIHR Strategic Partnership, Genome Canada will initiate a vital element of its Strategic Plan and CIHR will deliver on key objectives underpinning the CIHR Personalized Medicine Signature Initiative and the CIHR Data Harmonization Initiative.
March 2012
Operating Grant: Collaborative Health Research Projects (NSERC Partnered)
The Collaborative Health Research Projects (CHRP) program is a joint initiative between the Natural Sciences and Engineering Research Council (NSERC) and the Canadian Institutes of Health Research (CIHR). The CHRP program supports innovative interdisciplinary collaborative research projects requiring participation from the natural sciences or engineering community together with the health sciences community. The Institute of Cancer Research (ICR) has partnered with the CHRP program to advance the Personalized Medicine Signature Initiative research agenda.
December 2011
Large-Scale Applied Research Project Competition in Genomics and Personalized Health.
The Canadian Institutes of Health Research (CIHR), through its Personalized Medicine Signature Initiative, and Genome Canada will jointly support research projects in the area of genomics and personalized health, using the 2011 Large-Scale Applied Research Project Competition in Genomics and Personalized Health.
Background
CIHR is pleased to announce a strategic partnership with Genome Canada to collectively advance the Personalized Health Research agenda. CIHR's participation in this competition marks the launch of the CIHR Personalized Medicine Signature Initiative and advances all three of the initiative's stated objectives:
- Develop an evidence base on how to assess and, where appropriate, integrate innovative diagnostics (including laboratory diagnostics and medical imaging) into health policy and practice.
- Stimulate the discovery, validation, and translation of biomarkers, targets and genomic signatures for risk prevention and for diseases, which have the potential to promote strategies for prevention as improve the outcomes of therapeutic interventions by selecting tailoring of treatment choices to individual patient and disease characteristics
- Foster the development and validation of diagnostics based on such biomarkers, targets and genomic signatures, and of innovative devices for the application to patient practice
This strategic partnership provides an opportunity to maximize the effectiveness of the research communities, infrastructure and resources of both Genome Canada and CIHR. Genome Canada funded researchers provide leadership in large-scale applied genomic research projects and Genome Canada funded Science and Technology Innovation Centres (STICs) allow access to world leading Centres applying genomic and other "omic" technologies to scientific problems. CIHR brings access to their extensive health research community with expertise in health economics, health services and health policy, clinical epidemiology and clinical trials, clinical and basic research as well as existing and prospective biobanks.
CIHR's participation in this competition represents the first in a series of funding opportunities to be launched under the CIHR Personalized Medicine Signature Initiative. A key research priority area underscoring the CIHR Personalized Medicine Signature Initiative focuses on real world, evidence-based, comparative effectiveness of biomarkers and new or existing tools and technologies. This focus aims to create an evidence-base for new or existing biomarkers, tools and technologies, based on analytical validity (whether a test accurately identifies a genetic variant or biomarker), on clinical validity (whether a genetic variant, biomarker, or test accurately predicts the presence of disease or risk of disease), on clinical utility (whether a test will lead to an improved health outcome as well as the risks and benefits of the test), and on comparative effectiveness (helping to inform health care decisions by providing comparative evidence on the effectiveness, benefits, and harms of different treatment options).